Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Non-alcoholic fatty liver disease (NAFLD) is a global epidemic with a prevalence of 25%.
Currently therapies for NAFLD patients without diabetes mellitus (DM) are limited, and are
associated with various adverse side effects. Sodium-glucose cotransporter type-2 (SGLT2)
inhibitors can reduce hepatic fat content in patients with DM. However, the role of SGLT2
inhibitors in NAFLD patients without DM has not been investigated. Magnetic resonance
imaging-derived proton density fat fraction (MRI-PDFF) and liver stiffness measurement (LSM)
are non-invasive methods to diagnose hepatic steatosis and fibrosis/cirrhosis, respectively.
The investigators propose a double-blind, randomized, placebo-controlled trial to compare the
effects of empagliflozin (a type of SLGT2 inhibitors) versus placebo (in a 1:1 ratio) in
reducing hepatic fat content as measured by MRI-PDFF in NAFLD patients without DM. A total of
98 adult patients will be randomly sampled from the liver clinic in our local hospital.
Empagliflozin 10mg daily will be given to the treatment arm. The placebo pill will be
manufactured to be identical in appearance to the study drug. Eligible subjects will be
followed up until week 52, and will undergo clinical, anthropometric and laboratory
assessments (including liver function test and fasting blood) at baseline, week 6, 12, 26, 40
and 52. They will undergo LSM at baseline, week 26 and 52, and MRI-PDFF at baseline and week
52. The primary outcome will be a difference in change of liver fat content (measured by
MRI-PDFF) at week 52 from baseline between the two groups.
The study results will determine whether SGLT2 inhibitors can reduce hepatic steatosis in
NAFLD patients without DM.